Nomination Committee for Elicera Therapeutics appointed

November 4, 2021

Gothenburg, November 4, 2021 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immuno-oncological treatments focused on CAR T-cells and oncolytic viruses, announces that representatives of the largest owners have appointed the nomination committee ahead of the Annual General Meeting  2022.

On April 26, the Annual General Meeting established rules to guide the work of the Nomination Committee. The three largest owners on September 30 2021, were Magnus Essand, Di Yu and Jamal El-Mosleh, who together control 47.1% of the votes, and will be the election committee with Magnus Essand as chairman.

Shareholders who have comments and suggestions are asked to contact the Chairman of the Nomination Committee,  Magnus Essand with email

For further information please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB

Phone: +46 (0) 703 31 90 51

About Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The company has four drug candidates in development, two CAR T-cells and two oncolytic viruses, which are based on research conducted by Professor Magnus Essand's research group at Uppsala University. In addition, Elicera has a fully developed technology platform, iTANK, which can be used to optimize the effect of all CAR T-cell therapies under development and activate killer T-cells against cancer. Elicera's share (ELIC) is listed on the Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail:, tel: +468-503 000 50.

For more information, please visit

Download attachment (pdf)
< Back to press releases